Matches in DBpedia 2016-04 for { ?s ?p "Edith A. Perez [1], M.D., is a cancer specialist and an internationally known translational researcher who holds positions at both Genentech and Mayo Clinic. She is the Director of the Mayo Clinic Breast Cancer Translational Genomics Program started in 2009 and a Professor of Medicine at Mayo Medical School. In August 2015, Dr. Perez joined Genentech US Medical Affairs (USMA) as Vice President and Head of the BioOncology Medical Unit. In her new role, she will provide leadership for all BioOncology Medical Affairs activities in the United States. Throughout her career, Dr. Perez has developed a wide range of clinical trials exploring the use of new therapeutic agents for the treatment and prevention of breast cancer. In 2005, she, along with her team, revealed the results of the North Central Cancer Treatment Group N9831 Intergroup trial, of which she was the principal investigator. The results showed a considerable decrease in recurrence and increase in the survival of patients with HER2-positive breast cancer after the inclusion of trastuzumab to adjuvant chemotherapy. Following this result, Dr. Perez progressed into her present work, leading and helping develop basic research studies to evaluate the role of genetic markers in the development and aggressiveness of breast cancer. Dr. Perez has authored more than 300 peer-reviewed articles [2] and is invited frequently to lecture at national and international meetings and serves on the editorial boards of multiple academic journals. She has also held positions within Mayo Clinic, the American Association for Cancer Research, the American Society of Clinical Oncology, and the National Cancer Institute. Dr. Perez earned her medical degree from the University of Puerto Rico School of Medicine in San Juan and completed her residency in internal medicine at the Loma Linda University Medical Center in California. She served as general internist in the Division of National Health Services Corps, Los Angeles, and as a fellow in Hematology/Oncology at Martinez Veterans’ Administration Medical Center at the University of California, Davis School of Medicine. Dr. Perez is board certified in internal medicine, internal medicine – medical oncology and internal medicine – hematology.Dr. Perez is also a cofounder of the 26.2 with Donna The National Marathon to Finish Breast Cancer [3], which is dedicated to breast cancer research and care. It is the only marathon in the U.S. devoted solely to raising funds to end breast cancer."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Edith_A._Perez abstract "Edith A. Perez [1], M.D., is a cancer specialist and an internationally known translational researcher who holds positions at both Genentech and Mayo Clinic. She is the Director of the Mayo Clinic Breast Cancer Translational Genomics Program started in 2009 and a Professor of Medicine at Mayo Medical School. In August 2015, Dr. Perez joined Genentech US Medical Affairs (USMA) as Vice President and Head of the BioOncology Medical Unit. In her new role, she will provide leadership for all BioOncology Medical Affairs activities in the United States. Throughout her career, Dr. Perez has developed a wide range of clinical trials exploring the use of new therapeutic agents for the treatment and prevention of breast cancer. In 2005, she, along with her team, revealed the results of the North Central Cancer Treatment Group N9831 Intergroup trial, of which she was the principal investigator. The results showed a considerable decrease in recurrence and increase in the survival of patients with HER2-positive breast cancer after the inclusion of trastuzumab to adjuvant chemotherapy. Following this result, Dr. Perez progressed into her present work, leading and helping develop basic research studies to evaluate the role of genetic markers in the development and aggressiveness of breast cancer. Dr. Perez has authored more than 300 peer-reviewed articles [2] and is invited frequently to lecture at national and international meetings and serves on the editorial boards of multiple academic journals. She has also held positions within Mayo Clinic, the American Association for Cancer Research, the American Society of Clinical Oncology, and the National Cancer Institute. Dr. Perez earned her medical degree from the University of Puerto Rico School of Medicine in San Juan and completed her residency in internal medicine at the Loma Linda University Medical Center in California. She served as general internist in the Division of National Health Services Corps, Los Angeles, and as a fellow in Hematology/Oncology at Martinez Veterans’ Administration Medical Center at the University of California, Davis School of Medicine. Dr. Perez is board certified in internal medicine, internal medicine – medical oncology and internal medicine – hematology.Dr. Perez is also a cofounder of the 26.2 with Donna The National Marathon to Finish Breast Cancer [3], which is dedicated to breast cancer research and care. It is the only marathon in the U.S. devoted solely to raising funds to end breast cancer.".
- Q18389345 abstract "Edith A. Perez [1], M.D., is a cancer specialist and an internationally known translational researcher who holds positions at both Genentech and Mayo Clinic. She is the Director of the Mayo Clinic Breast Cancer Translational Genomics Program started in 2009 and a Professor of Medicine at Mayo Medical School. In August 2015, Dr. Perez joined Genentech US Medical Affairs (USMA) as Vice President and Head of the BioOncology Medical Unit. In her new role, she will provide leadership for all BioOncology Medical Affairs activities in the United States. Throughout her career, Dr. Perez has developed a wide range of clinical trials exploring the use of new therapeutic agents for the treatment and prevention of breast cancer. In 2005, she, along with her team, revealed the results of the North Central Cancer Treatment Group N9831 Intergroup trial, of which she was the principal investigator. The results showed a considerable decrease in recurrence and increase in the survival of patients with HER2-positive breast cancer after the inclusion of trastuzumab to adjuvant chemotherapy. Following this result, Dr. Perez progressed into her present work, leading and helping develop basic research studies to evaluate the role of genetic markers in the development and aggressiveness of breast cancer. Dr. Perez has authored more than 300 peer-reviewed articles [2] and is invited frequently to lecture at national and international meetings and serves on the editorial boards of multiple academic journals. She has also held positions within Mayo Clinic, the American Association for Cancer Research, the American Society of Clinical Oncology, and the National Cancer Institute. Dr. Perez earned her medical degree from the University of Puerto Rico School of Medicine in San Juan and completed her residency in internal medicine at the Loma Linda University Medical Center in California. She served as general internist in the Division of National Health Services Corps, Los Angeles, and as a fellow in Hematology/Oncology at Martinez Veterans’ Administration Medical Center at the University of California, Davis School of Medicine. Dr. Perez is board certified in internal medicine, internal medicine – medical oncology and internal medicine – hematology.Dr. Perez is also a cofounder of the 26.2 with Donna The National Marathon to Finish Breast Cancer [3], which is dedicated to breast cancer research and care. It is the only marathon in the U.S. devoted solely to raising funds to end breast cancer.".